Sotera Health Company

NasdaqGS:SHC 株式レポート

時価総額：US$5.4b

Sotera Health 将来の成長

Future 基準チェック /46

Sotera Health利益と収益がそれぞれ年間21.1%と5.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に26.6% 20.2%なると予測されています。

主要情報

21.1%

収益成長率

20.20%

EPS成長率

Life Sciences 収益成長18.8%
収益成長率5.6%
将来の株主資本利益率26.64%
アナリストカバレッジ

Good

最終更新日07 Aug 2026

今後の成長に関する最新情報

分析記事 • Nov 07

Results: Sotera Health Company Beat Earnings Expectations And Analysts Now Have New Forecasts

Sotera Health Company ( NASDAQ:SHC ) investors will be delighted, with the company turning in some strong numbers with...

Recent updates

ナラティブ更新 • Aug 07

SHC: Raised Outlook And Margin Assumptions Will Support Steady Future Returns

Analysts have raised their price target on Sotera Health from $16.00 to about $18.64, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E levels. What’s in the News for Sotera Health Sotera Health reported strong second quarter and first half 2026 results, with high single digit growth across its business units.
Seeking Alpha • Jul 24

Sotera Health: Why We Plan To Own This For Many Years

Summary Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. At their November 2024 Investor Day, management outlined a 2025-2027 plan targeting 5%-7% organic revenue growth and 5%-8% adjusted EBITDA growth, with at least 50bps of EBITDA margin expansion annually. Shader comes from Viant Medical, where he served as CEO since 2019, and holds a Stanford MBA. Once a medical device is validated for sterilization at a specific facility, changing that facility requires extensive regulatory work, testing, and approval. If the EPA finalizes the strict 2024 rule, Sotera's capital spend is justified, and competitors without the scale to absorb compliance costs will exit. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 25

SHC: Equity Raise And 2026 Earnings Guidance Will Drive Future Upside

The analyst price target for Sotera Health has been nudged higher from $20.13 to about $20.22, reflecting analysts' updated modeling around fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sotera Health Sotera Health filed a follow on equity offering of 31,838,253 shares of common stock, classified as a follow on equity offering event.
ナラティブ更新 • Jun 04

SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside

Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.
分析記事 • May 13

Sotera Health's (NASDAQ:SHC) Performance Is Even Better Than Its Earnings Suggest

Sotera Health Company ( NASDAQ:SHC ) just reported healthy earnings but the stock price didn't move much. Investors are...
ナラティブ更新 • May 12

SHC: Equity Raise And Reaffirmed 2026 Guidance Will Support Upside

Analysts have trimmed their price target on Sotera Health slightly from $20.50 to $20.13, citing updated assumptions for long term revenue growth, profit margins, and future P/E multiples. What's in the News Sotera Health plans a CEO transition, with Alton Shader set to become CEO and join the board on May 26, 2026.
ナラティブ更新 • Apr 27

SHC: Follow On Equity Raise And 2026 Guidance Will Support Upside

Analysts now see a slightly lower price target for Sotera Health, trimming it from $20.75 to $20.50 as small adjustments to fair value, discount rate, revenue growth, profit margin and forward P/E estimates feed into their updated view. What's in the News Sotera Health completed a follow-on equity offering of 25,000,000 common shares, raising about US$381.75m at a price of US$15.27 per share (Key Developments).
ナラティブ更新 • Apr 10

SHC: Equity Raise And 2026 Revenue Guidance Will Support Future Upside Potential

Analysts have maintained their $20.75 price target on Sotera Health, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions underpinning the updated view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 common shares, raising about $381.75 million at a price of $15.27 per share (company filing).
ナラティブ更新 • Mar 27

SHC: Equity Raise And 2026 Guidance Will Support Future Upside Potential

Analysts are maintaining a price target of $20.75 for Sotera Health, with only modest tweaks to assumptions such as discount rate, long term revenue growth, profit margin and future P/E multiples, supporting an unchanged valuation view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 shares of common stock, raising approximately $381.75 million at a price of about $15.27 per share (company filing).
ナラティブ更新 • Mar 10

SHC: Organic Investment And Margin Expansion Will Support Future Upside Potential

Analysts have raised their price target on Sotera Health to $20.75 from $20.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect refreshed views on the company’s risk profile and earnings power. What's in the News Sotera Health filed a follow on equity offering of 25,000,000 shares of common stock, and later completed the offering for proceeds of US$381.75m at a price of US$15.27 per share, indicating recent access to equity capital markets.
ナラティブ更新 • Feb 24

SHC: Organic Investment And Deleveraging Will Support Future Upside Potential

Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.
ナラティブ更新 • Feb 10

SHC: Organic Capital Deployment Will Support Deleveraging And Undervalued Upside

Analysts have maintained their price target for Sotera Health at approximately US$20.44, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E used in their valuation models. What's in the News Sotera Health signaled it will continue to focus its capital on organic growth initiatives, with CEO Michael Petras highlighting this as the primary use of funds during the JPMorgan Healthcare Conference (Key Developments).
ナラティブ更新 • Jan 26

SHC: Equity Offering And Capital Allocation Priorities Will Guide Balanced Outlook

Analysts have modestly adjusted their price expectations for Sotera Health, with the updated target now at approximately US$20.44. This reflects small tweaks to assumptions such as the discount rate, long-term revenue growth, profit margin and future P/E.
新しいナラティブ • Jan 24

Bullish View Expects Sterilization Demand And Cobalt 60 Stability To Support Long-Term Upside

Catalysts About Sotera Health Sotera Health provides sterilization services and lab testing that support global health care and medical products. What are the underlying business or industry changes driving this perspective?
ナラティブ更新 • Jan 12

SHC: Follow-On Equity Offering And Lock-Up Terms Will Shape Balanced Outlook

Analysts have lifted their price target for Sotera Health to US$20.44 from US$18.93, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Sotera Health completed a follow on equity offering of 30,000,000 common shares, raising about US$471 million at a price of US$15.70 per share with a US$0.049 discount per share (Key Developments).
分析記事 • Jan 09

Is Sotera Health Company (NASDAQ:SHC) Potentially Undervalued?

Sotera Health Company ( NASDAQ:SHC ), is not the largest company out there, but it led the NASDAQGS gainers with a...
ナラティブ更新 • Dec 15

SHC: Follow-On Equity Offering Will Drive Bullish Share Performance Next Year

Narrative Update Analysts have modestly raised their price target on Sotera Health, citing fine tuned assumptions around discount rates, revenue growth, margins, and future earnings multiples as justification for a slightly higher implied fair value near $18.93 per share. What's in the News Sotera Health has completed a follow-on equity offering of approximately $471 million, issuing 30 million shares of common stock at about $15.70 per share (Key Developments) The company has filed a separate follow-on equity offering totaling roughly $480.3 million for 30 million shares of common stock, with an indicated price of about $16.01 per share (Key Developments) Executive officers, directors and selling stockholders have agreed to a lock-up on 284,093,929 common shares, restricting most sales and hedging activity from November 6, 2025 to December 7, 2025 (Key Developments) Certain restricted stock units held by insiders are also subject to the same 31-day lock-up period ending December 7, 2025 (Key Developments) Options held by executives, directors and selling stockholders will likewise be restricted during the November 6 to December 7, 2025 lock-up window (Key Developments) Valuation Changes Fair Value: Unchanged at an implied price of approximately $18.93 per share.
ナラティブ更新 • Nov 30

SHC: Follow-On Offering And Lock-Up Expiration Will Shape Shares Next Year

Analysts have maintained their price target for Sotera Health at $18.93, citing consistent expectations for growth and profitability metrics along with minor adjustments to underlying discount rates and projected price-to-earnings ratios. What's in the News Sotera Health Company has completed a Follow-on Equity Offering valued at $471 million, issuing 30 million shares of common stock at $15.70 each (Key Developments).
ナラティブ更新 • Nov 16

SHC: Improved Profit Margins Will Drive Future Share Price Upside

Analysts have raised their price target for Sotera Health from $17.00 to $18.93 per share. They cite an improved profit margin outlook despite slightly lower revenue growth projections.
分析記事 • Nov 11

Sotera Health's (NASDAQ:SHC) Conservative Accounting Might Explain Soft Earnings

The most recent earnings report from Sotera Health Company ( NASDAQ:SHC ) was disappointing for shareholders. However...
分析記事 • Nov 07

Results: Sotera Health Company Beat Earnings Expectations And Analysts Now Have New Forecasts

Sotera Health Company ( NASDAQ:SHC ) investors will be delighted, with the company turning in some strong numbers with...
ナラティブ更新 • Nov 01

SHC: Recent Equity Offerings And Lock-Up Expiry Will Shape Market Outlook

Narrative Update on Sotera Health Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.
ナラティブ更新 • Oct 17

Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets

Narrative Update: Sotera Health Analyst Price Target Adjustment Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.
ナラティブ更新 • Oct 03

Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets

Analysts have modestly raised their price target for Sotera Health from $16.00 to approximately $16.33. This reflects incremental updates in growth and valuation assumptions.
ナラティブ更新 • Aug 10

Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets

Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.

業績と収益の成長予測

NasdaqGS:SHC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20281,399285N/A4465
12/31/20271,3212462384219
12/31/20261,2472061093469
6/30/20261,216163113292N/A
3/31/20261,18911897261N/A
12/31/20251,16478149287N/A
9/30/20251,1505587240N/A
6/30/20251,12524113266N/A
3/31/20251,10725106270N/A
12/31/20241,1004445224N/A
9/30/20241,12070104282N/A
6/30/20241,0984032226N/A
3/31/20241,07755-377-172N/A
12/31/20231,04951-363-148N/A
9/30/2023991-306-381-159N/A
6/30/2023976-268-342-133N/A
3/31/2023988-26170262N/A
12/31/20221,004-23496278N/A
9/30/202299312190242N/A
6/30/2022971123127256N/A
3/31/2022956135159275N/A
12/31/2021931115179282N/A
9/30/202190736156237N/A
6/30/20218819127202N/A
3/31/2021842-26110171N/A
12/31/2020818-3967121N/A
9/30/2020795-2355109N/A
6/30/2020790-2868124N/A
3/31/2020772-29N/A116N/A
12/31/2019778-21N/A149N/A
12/31/2018746-6N/A120N/A

アナリストによる今後の成長予測

収入対貯蓄率: SHCの予測収益成長率 (年間21.1% ) は 貯蓄率 ( 3.7% ) を上回っています。

収益対市場: SHCの収益 ( 21.1% ) はUS市場 ( 17.1% ) よりも速いペースで成長すると予測されています。

高成長収益: SHCの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: SHCの収益 ( 5.6% ) US市場 ( 13% ) よりも低い成長が予測されています。

高い収益成長: SHCの収益 ( 5.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SHCの 自己資本利益率 は、3年後には高くなると予測されています ( 26.6 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/17 02:38
終値2026/08/17 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Sotera Health Company 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14

アナリスト機関
Michael PolarkBaird
Luke SergottBarclays
Sean DodgeBMO Capital Markets Equity Research